Compare Stocks: BETRF, NRXP, UNCY, and MIST

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BETRF BetterLife Pharma	$0.22 -0.3%	$0.19	$0.03 ▼ $0.33	$36.18M	0.22	109,468 shs	34,000 shs
MIST Milestone Pharmaceuticals	$1.20 -0.8%	$1.19	$1.00 ▼ $3.06	$149.40M	0.98	1.77 million shs	1.58 million shs
NRXP NRx Pharmaceuticals	$3.49 +1.7%	$3.68	$1.62 ▼ $5.05	$151.10M	2.19	1.10 million shs	485,173 shs
UNCY Unicycive Therapeutics	$5.16 -2.6%	$5.34	$3.71 ▼ $8.74	$143.73M	1.79	731,929 shs	492,855 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BETRF BetterLife Pharma	0.00%	-6.69%	-21.50%	+420.19%	+238.32%
MIST Milestone Pharmaceuticals	0.00%	+3.45%	+1.69%	-2.44%	-32.58%
NRXP NRx Pharmaceuticals	0.00%	-1.69%	+12.94%	-15.70%	+34.23%
UNCY Unicycive Therapeutics	0.00%	-1.90%	+2.18%	-25.43%	+20.28%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BETRF BetterLife Pharma	$0.22 -0.3%	$0.19	$0.03 ▼ $0.33	$36.18M	0.22	109,468 shs	34,000 shs
MIST Milestone Pharmaceuticals	$1.20 -0.8%	$1.19	$1.00 ▼ $3.06	$149.40M	0.98	1.77 million shs	1.58 million shs
NRXP NRx Pharmaceuticals	$3.49 +1.7%	$3.68	$1.62 ▼ $5.05	$151.10M	2.19	1.10 million shs	485,173 shs
UNCY Unicycive Therapeutics	$5.16 -2.6%	$5.34	$3.71 ▼ $8.74	$143.73M	1.79	731,929 shs	492,855 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BETRF BetterLife Pharma	0.00%	-6.69%	-21.50%	+420.19%	+238.32%
MIST Milestone Pharmaceuticals	0.00%	+3.45%	+1.69%	-2.44%	-32.58%
NRXP NRx Pharmaceuticals	0.00%	-1.69%	+12.94%	-15.70%	+34.23%
UNCY Unicycive Therapeutics	0.00%	-1.90%	+2.18%	-25.43%	+20.28%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BETRF BetterLife Pharma	0.00	N/A	N/A	N/A
MIST Milestone Pharmaceuticals	2.71	Moderate Buy	$6.40	433.33% Upside
NRXP NRx Pharmaceuticals	2.43	Hold	$34.50	888.54% Upside
UNCY Unicycive Therapeutics	2.57	Moderate Buy	$18.75	263.37% Upside

Current Analyst Ratings Breakdown

Latest BETRF, NRXP, UNCY, and MIST Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/3/2026	MIST Milestone Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/26/2026	NRXP NRx Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/26/2026	NRXP NRx Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/25/2026	NRXP NRx Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/20/2026	UNCY Unicycive Therapeutics	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Speculative Buy	$13.00 ➝ $15.00
8/20/2026	MIST Milestone Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$3.00
8/19/2026	UNCY Unicycive Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/18/2026	NRXP NRx Pharmaceuticals	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$10.00
8/13/2026	UNCY Unicycive Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$37.00 ➝ $25.00
8/12/2026	UNCY Unicycive Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$22.00 ➝ $20.00
8/10/2026	NRXP NRx Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 9/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BETRF BetterLife Pharma	N/A	N/A	N/A	N/A	($0.03) per share	N/A
MIST Milestone Pharmaceuticals	$1.55M	96.39	N/A	N/A	$0.15 per share	8.00
NRXP NRx Pharmaceuticals	$1.23M	122.86	N/A	N/A	N/A	∞
UNCY Unicycive Therapeutics	N/A	N/A	N/A	N/A	$1.91 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BETRF BetterLife Pharma	-$1.07M	N/A	N/A	N/A	N/A	N/A	N/A	-772.34%	N/A
MIST Milestone Pharmaceuticals	-$63.06M	-$0.69	N/A	N/A	N/A	N/A	-288.33%	-58.27%	11/11/2026 (Estimated)
NRXP NRx Pharmaceuticals	-$28.62M	-$0.55	N/A	N/A	N/A	-691.81%	N/A	-63.92%	11/13/2026 (Estimated)
UNCY Unicycive Therapeutics	-$26.56M	-$1.75	N/A	2.39	N/A	N/A	-91.50%	-61.47%	11/11/2026 (Estimated)

Latest BETRF, NRXP, UNCY, and MIST Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/17/2026	Q2 2026	NRXP NRx Pharmaceuticals	-$0.1067	-$0.44	-$0.3333	-$0.44	$1.33 million	$1.10 million
8/12/2026	Q2 2026	MIST Milestone Pharmaceuticals	-$0.1950	-$0.21	-$0.0150	-$0.21	$0.82 million	$0.56 million
8/12/2026	Q2 2026	UNCY Unicycive Therapeutics	-$0.4710	-$0.06	+$0.4110	-$0.06	$22.22 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BETRF BetterLife Pharma	N/A	N/A	N/A	N/A	N/A
MIST Milestone Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
UNCY Unicycive Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BETRF BetterLife Pharma	N/A	0.04	0.04
MIST Milestone Pharmaceuticals	3.25	8.13	7.92
NRXP NRx Pharmaceuticals	N/A	0.86	0.86
UNCY Unicycive Therapeutics	N/A	3.81	3.81

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BETRF BetterLife Pharma	0.01%
MIST Milestone Pharmaceuticals	86.18%
NRXP NRx Pharmaceuticals	4.27%
UNCY Unicycive Therapeutics	40.42%

Insider Ownership

Company	Insider Ownership
BETRF BetterLife Pharma	34.77%
MIST Milestone Pharmaceuticals	5.03%
NRXP NRx Pharmaceuticals	6.40%
UNCY Unicycive Therapeutics	6.03%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BETRF BetterLife Pharma	7	163.25 million	106.49 million	Not Optionable
MIST Milestone Pharmaceuticals	30	124.50 million	118.24 million	Optionable
NRXP NRx Pharmaceuticals	2	43.30 million	40.53 million	Optionable
UNCY Unicycive Therapeutics	9	27.86 million	26.18 million	Not Optionable

BETRF, NRXP, UNCY, and MIST Headlines

Recent News About These Companies

UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law

September 5 at 1:18 PM | businesswire.com

UNCY INVESTOR ALERT: Securities Class Action Filed Against Unicycive Therapeutics, Inc. - Investors Encouraged to Contact Kirby McInerney LLP

September 4 at 11:42 PM | tmcnet.com

UNCY INVESTOR ALERT: Securities Class Action Filed Against Unicycive Therapeutics, Inc. -- Investors Encouraged to Contact Kirby McInerney LLP

September 4 at 10:00 PM | gurufocus.com

UNCY INVESTOR ALERT: Securities Class Action Filed Against Unicycive Therapeutics, Inc. – Investors Encouraged to Contact Kirby McInerney LLP

September 4 at 8:00 PM | businesswire.com

UNICYCIVE INVESTOR ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Unicycive Therapeutics, Inc. and Encourages Investors to Contact the Firm

September 4 at 3:06 PM | globenewswire.com

UNCY INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Unicycive Therapeutics, Inc. Investors – Holzer & Holzer, LLC Encourages Investors With Losses to Contact the Firm

September 4 at 11:05 AM | globenewswire.com

Law Offices of Howard G. Smith Encourages Unicycive Therapeutics, Inc. (UNCY) Shareholders To Inquire About Securities Fraud Class Action

September 4 at 11:00 AM | businesswire.com

Robbins LLP Informs Investors of the Unicycive Therapeutics, Inc. Securities Class Action

September 3 at 8:08 PM | businesswire.com

UNCY CLASS ACTION NOTICE: Glancy Prongay Wolke & Rotter LLP Files Securities Fraud Lawsuit On Behalf Of Unicycive Therapeutics, Inc. Investors

September 3 at 8:00 PM | businesswire.com

Unicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

September 1, 2026 | globenewswire.com

Analysts Are Bullish on Top Healthcare Stocks: Unicycive Therapeutics (UNCY), Praxis Precision Medicines (PRAX)

August 21, 2026 | theglobeandmail.com

Unicycive Therapeutics (NASDAQ:UNCY) Upgraded at Zacks Research

August 21, 2026 | marketbeat.com

Research Analysts Set Expectations for UNCY Q3 Earnings

August 17, 2026 | marketbeat.com

Noble Financial Has Positive Forecast for UNCY Q3 Earnings

August 17, 2026 | marketbeat.com

Unicycive Therapeutics (NASDAQ:UNCY) Upgraded to Hold at Wall Street Zen

August 15, 2026 | marketbeat.com

Noble Financial Has Pessimistic View of UNCY Q2 Earnings

August 14, 2026 | marketbeat.com

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Given Consensus Rating of "Hold" by Brokerages

August 13, 2026 | marketbeat.com

Unicycive Therapeutics shares rise after second-quarter loss beats forecasts

August 13, 2026 | msn.com

Unicycive Therapeutics (NASDAQ:UNCY) Announces Quarterly Earnings Results

August 12, 2026 | marketbeat.com

Unicycive Therapeutics Reports FDA Facility Inspection Assigned for OLC Manufacturing Vendor, Plans NDA Resubmission After Successful Inspection

August 12, 2026 | quiverquant.comQ

Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update

August 12, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BETRF, NRXP, UNCY, and MIST Company Descriptions

BetterLife Pharma OTCMKTS:BETRF

$0.22 0.00 (-0.27%)

As of 09/4/2026 01:48 PM Eastern

BetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of compounds for the treatment of mental disorders in Canada. It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections. The company's products pipeline includes BETR-001 for the treatment of major depressive disorder, anxiety, and neuropathic pain and other neuro-psychiatric and neurological disorders; and BETR-002 to treat benzodiazepine dependency, anxiety, and neurodegenerative disorders. It is also developing MM-003, which has completed Phase II clinical trials for treatment of COVID-19 and other respiratory viral infections; and MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia that has completed Phase II clinical trials. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.

Milestone Pharmaceuticals NASDAQ:MIST

$1.20 -0.01 (-0.83%)

As of 09/4/2026 04:00 PM Eastern

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

NRx Pharmaceuticals NASDAQ:NRXP

$3.49 +0.06 (+1.75%)

As of 09/4/2026 04:00 PM Eastern

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

Unicycive Therapeutics NASDAQ:UNCY

$5.16 -0.14 (-2.64%)

As of 09/4/2026 04:00 PM Eastern

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BETRF, NRXP, UNCY, and MIST Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BETRF, NRXP, UNCY, and MIST Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BETRF, NRXP, UNCY, and MIST Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BETRF, NRXP, UNCY, and MIST Company Descriptions

BetterLife Pharma OTCMKTS:BETRF

Milestone Pharmaceuticals NASDAQ:MIST

NRx Pharmaceuticals NASDAQ:NRXP

Unicycive Therapeutics NASDAQ:UNCY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BETRF, NRXP, UNCY, and MIST Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BETRF, NRXP, UNCY, and MIST Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BETRF, NRXP, UNCY, and MIST Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BETRF, NRXP, UNCY, and MIST Company Descriptions

BetterLife Pharma OTCMKTS:BETRF

Milestone Pharmaceuticals NASDAQ:MIST

NRx Pharmaceuticals NASDAQ:NRXP

Unicycive Therapeutics NASDAQ:UNCY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools